Market Overview

UPDATE: Bank of America Merrill Lynch Initiates Coverage on AbbVie with Buy Rating, $40 PT

Related ABBV
Markets Close Higher Ahead Of Busy Earnings Season
Shire Shares Volatile Surrounding Speculation And Confirmation Of AbbVie Meeting
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

In a report published Friday, Bank of America Merrill Lynch initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and $40.00 price target.

BofA Merrill Lynch noted, “ABBV is unique among the US Major Pharma companies given its significant product concentration (45% of 2011 revenues were generated by a single product), Humira. Despite this, we are bullish on ABBV given its attractive valuation, above-average dividend yield, and the potential for the pipeline to deliver a blockbuster HCV franchise over the medium term. We conservatively include no real contribution from the rest of the pipeline despite the fact that we continue to model robust R&D spend.””

AbbVie closed on Thursday at $34.83.

Posted-In: Bank of America Merrill LynchAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free